knowledge -WSS

knowledge

author：entertainment 2025-10-02 18:05:55 - browse：8

SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing giant Illumina has begun to lay off 10% of its research and development team, according to internal emails obtained and reviewed by STAT.

The layoffs, which began last Wednesday, impact research teams across the company’s California sites in San Diego and Foster City, as well as locations in Madison, Wisconsin; Singapore; and the United Kingdom. Alex Aravanis, the company’s chief technology officer, noted in an internal message that these cuts affect a tenth of research and development staff. The company’s also planning to shut down all lab-based research and development work in Foster City, according to a note from Steve Barnard, vice president of technology development.

Barnard’s note mentions that all affected employees have already been notified. And a separate message from interim CEO Charles Dadswell makes clear last week’s layoffs won’t be the last.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： A double vaccine crisis is endangering millions of children

WSS

A new drug could help frostbite victims avoid its ravages

Organ transplantation is at a crossroads. Major reform is needed

Will.i.am, Britney Spears release new single, 'Mind Your Business'

New study raises questions about niacin and heart health

Marvel Studios reveals new trailer for 'The Marvels': Watch here

In 'major milestone,' FDA approves first cell therapy for solid tumors

focus

knowledge

focus

ChatGPT in medicine: STAT answers readers' burning questions

Why an extreme heat and wildfire smoke combination can be so dangerous

Continuity nursing helped my family in our darkest PICU moments

In new study, freeze

Cancer drug shortages should be causing more outrage

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Anesthesiologist group: stop taking Ozempic before surgery

New CMS data security rules will hurt Medicare, Medicaid research

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA official pushes for dedicated emerging pathogens team

hotspot

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

As Taiwan prepares for anti

Researchers tackle phage therapy hurdles for wider adoption

As AI regulations shape up, health tech startups beg for clarity

MD Anderson's Padmanee Sharma responds to research credit suit

A double vaccine crisis is endangering millions of children

leisure time

hotspot

leisure time

focus